Posted Dec. 23, 2013 at 2:23 p.m.

Premium Lock Pozen's 'safer aspirin' delayed pending additional clinical study

Published: 2013-12-23 14:23:55
Updated: 2013-12-23 14:23:55

Chairman, CEO John Plachetka Chairman, CEO John Plachetka Image 1 of 2 · Next Image…

Pozen will conduct a phase I trial comparing two dosages of its safer aspirin in order to answer FDA questions about its effects. Read more about the additional clinical study....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll